Test Code SP7CS Septin-7 Antibody, Cell-Binding Assay, Serum
Specimen Required
Only orderable as a reflex. For more information see:
-ENS2 / Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Serum
-MDS2 / Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Serum
-MAS1 / Myelopathy, Autoimmune/Paraneoplastic Evaluation, Serum
Useful For
Detecting septin-7 IgG by cell-binding assay using serum specimens
Testing Algorithm
If the indirect immunofluorescence (IFA) pattern suggests septin-7, then this test and septin-7 antibody IFA titer will be performed at an additional charge.
Method Name
Only orderable as a reflex. For more information see:
-ENS2 / Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Serum
-MDS2 / Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Serum
-MAS1 / Myelopathy, Autoimmune/Paraneoplastic Evaluation, Serum
Cell-Binding Assay (CBA)
Reporting Name
Septin-7 CBA, SSpecimen Type
SerumSpecimen Minimum Volume
See Specimen Required
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Refrigerated (preferred) | 28 days | |
Frozen | 28 days | ||
Ambient | 72 hours |
Reject Due To
Gross hemolysis | Reject |
Gross lipemia | Reject |
Gross icterus | Reject |
Clinical Information
Neurological phenotypes for septin-7 IgG positive patients include encephalopathy, myelopathy, encephalomyelopathy, painful myelopolyradiculopathy, and episodic ataxia. Psychiatric symptoms are also common with encephalopathic symptoms. Septin-7 IgG is also associated with cancer. Positive response to immunotherapy.
Reference Values
Only orderable as a reflex. For more information see:
-ENS2 / Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Serum
-MDS2 / Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Serum
-MAS1 / Myelopathy, Autoimmune/Paraneoplastic Evaluation, Serum
Negative
Interpretation
Seropositivity for septin antibodies by immunofluorescence is consistent with a diagnosis of autoimmune disease of the central nervous system. Cell-binding assay (CBA) testing for septin-7 IgG is required to confirm the diagnosis. Seropositivity for septin-7 IgG by CBA confirms a diagnosis of autoimmune disease of the central nervous system. A paraneoplastic cause should be considered in patients with septin-7 IgG.
Cautions
Negative results for septin-7 IgG by cell-binding assay do not exclude neurological autoimmunity or cancer.
Method Description
Patient specimen is applied to a composite slide containing transfected and nontransfected HEK-293 cells. After incubation and washing, fluorescein-conjugated goat-antihuman IgG is applied to detect the presence of patient IgG binding.(Package insert: IIFT: Neurology Mosaics, Instructions for the indirect immunofluorescence test. EUROIMMUN; FA_112d-1_A_UK_C13, 02/2019)
Day(s) Performed
Monday through Sunday
Report Available
5 to 10 daysSpecimen Retention Time
28 daysPerforming Laboratory
Mayo Clinic Laboratories in RochesterTest Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
86255
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
SP7CS | Septin-7 CBA, S | In Process |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
615873 | Septin-7 CBA, S | In Process |